Newsroom

RALEIGH, N.C.--(BUSINESS WIRE)--Ralliant Corporation (“Ralliant” or the “Company”) (NYSE: RAL) today announced financial results for the fourth quarter and full year of 2025. For the fourth quarter, revenue of $555 million increased 1% year-over-year and 5% sequentially. Net loss was $(1.4) billion or $(12.10) per diluted share, including a non-cash goodwill impairment charge of $1.4 billion recorded in the Test & Measurement segment, primarily driven by revised expectations for the EA Elek...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--GE Vernova (NYSE: GEV) is pleased to announce the closing of its previously announced registered public offering of Senior Notes. GE Vernova intends to use the net proceeds from the offering for general corporate purposes, including financing a portion of the acquisition of the remaining fifty percent stake of Prolec GE that closed on February 2, 2026. The offering consists of the following tranches: $600 million aggregate principal amount of 4.250% Senior Not...

TORONTO--(BUSINESS WIRE)--Sangoma Technologies Corporation (TSX: STC; Nasdaq: SANG) (“Sangoma” or the “Company”), a trusted industry leader uniquely offering businesses a choice of on-premises, cloud-based, or hybrid Communications as a Service solutions, today announced its second quarter financial results and unaudited condensed consolidated interim financial statements for the three and six month periods ended December 31, 2025. All amounts are expressed in US dollars unless otherwise stated...

威斯康辛州麥迪森--(BUSINESS WIRE)--(美國商業資訊)-- 中國國家藥品監督管理局(NMPA)已核准OncoMate® 微衛星不穩定性(MSI)檢測試劑盒為中國三類體外診斷醫療器材。該試劑盒擬做為伴隨診斷試劑，用於辨識高微衛星不穩定性(MSI-H)實質腫瘤病患，以接受美國紐澤西州拉威市Merck & Co., Inc.的抗PD-1療法——KEYTRUDA® (pembrolizumab)治療。這是Promega首款獲得NMPA核准的伴隨診斷試劑。 Promega全球臨床市場總監Alok Sharma表示：「此次核准代表中國在實現更具個人化、更有效的癌症治療方面邁出了重要一步。我們很驕傲能與製藥企業合作，提供全球解決方案，擴大創新技術和挽救生命的有效療法的可及性。」 中國仍是全球癌症負擔最重的國家之一，實質腫瘤占全國癌症確診病例的絕大多數。儘管腫瘤治療領域取得了諸多進展，但大多數晚期實質腫瘤病患在一線治療後最終仍會出現疾病惡化，因此迫切需要能指導更有效的替代治療策略的工具。OncoMate® MSI檢測試劑盒是一種以聚合酶鏈反應(PCR)技術為基礎的檢測方法，旨在...

威斯康星州麦迪逊--(BUSINESS WIRE)--(美国商业资讯)-- 中国国家药品监督管理局(NMPA)已批准OncoMate® 微卫星不稳定性(MSI)检测试剂盒作为中国三类体外诊断医疗器械。该试剂盒拟作为伴随诊断试剂，用于识别高微卫星不稳定性(MSI-H)实体瘤患者，以接受美国新泽西州拉威市Merck & Co., Inc.的抗PD-1疗法——KEYTRUDA® (pembrolizumab)治疗。这是Promega首款获得NMPA批准的伴随诊断试剂。 Promega全球临床市场总监Alok Sharma表示：“此次批准标志着中国在实现更具个性化、更有效的癌症治疗方面迈出了重要一步。我们很自豪能与制药企业合作，提供全球解决方案，扩大创新技术和挽救生命的有效疗法的可及性。” 中国仍是全球癌症负担最重的国家之一，实体瘤占全国癌症确诊病例的绝大多数。尽管肿瘤治疗领域取得了诸多进展，但大多数晚期实体瘤患者在一线治疗后最终仍会出现疾病进展，因此迫切需要能指导更有效的替代治疗策略的工具。OncoMate® MSI检测试剂盒是一种基于聚合酶链反应(PCR)技术的检测方法，旨在评估肿...

DUBLIN--(BUSINESS WIRE)--Allegion plc (NYSE: ALLE), a leading global security products and solutions provider, today announced that its board of directors declared a quarterly dividend of $0.55 per ordinary share of the company – representing an 8% increase from 2025 and the company’s 12th consecutive annual dividend increase. The dividend is payable on March 31, 2026, to shareholders of record on March 13, 2026. About Allegion At Allegion (NYSE: ALLE), we design and manufacture innovative secu...

TAMPA, Fla.--(BUSINESS WIRE)--Sila Realty Trust Announces Fourth Quarter and Year Ended 2025 Earnings Release Date and Conference Call...

NEW YORK--(BUSINESS WIRE)--Plug Power Inc. Sued for Securities Fraud after it Suspends Plans to Construct Hydrogen Production Facilities - Investors are Urged to Contact BFA Law...

DAVIDSON, N.C.--(BUSINESS WIRE)--Curtiss-Wright Corporation (NYSE: CW) today announced that the Board of Directors declared a quarterly dividend of twenty-four cents ($0.24) per share on Curtiss-Wright Common Stock, payable April 13, 2026, to stockholders of record as of March 26, 2026. About Curtiss-Wright Corporation Curtiss-Wright Corporation (NYSE: CW) is a global integrated business that provides highly engineered products, solutions and services mainly to Aerospace & Defense markets,...

VALLEY FORGE, Pa.--(BUSINESS WIRE)--UGI Corporation (NYSE: UGI) today reported financial results for the fiscal quarter ended December 31, 2025. HIGHLIGHTS Q1 GAAP diluted earnings per share ("EPS") of $1.34 and adjusted diluted EPS of $1.26 compared to GAAP diluted EPS of $1.74 and adjusted diluted EPS of $1.37 in the prior-year period. Q1 reportable segments earnings before interest expense and income taxes1 ("EBIT") of $441 million compared to $420 million in the prior-year period. In Januar...